Presented by Dr Anups De Silva, a Consultant Gastroenterologist at Norfolk and Norwich University Hospital.
About this webinar
This session is presented by Dr Anups De Silva, a Consultant Gastroenterologist at Norfolk and Norwich University Hospital. The webinar formed part of the Primary Care Nursing Live virtual conference held in March 2022. All talks from PCN Live are CPD certified and can be watched on-demand now by visiting www.primarycarenursinglive.com.
The webinar gives a brief overview of inflammatory bowel disease (IBD), discussing the use of mesalazine in the treatment of ulcerative colitis and locally acting steroids in the treatment of Crohn’s disease. Dr De Silva speaks about ways in which IBD therapy can be optimised in primary care, methods to support IBD patient self-management and approaches which may aid admission avoidance.
This session has been sponsored by Tillotts and products will be discussed during the presentation.
Prescribing Information:
Octasa (mesalazine) prescribing information: https://www.tillotts.co.uk/octasa-pi-page/
Entocort CR (budesonide) capsules prescribing information: https://www.tillotts.co.uk/entocort-capsules-pi/
Entocort (budesonide) Enema prescribing information: https://www.tillotts.co.uk/entocort-enema-pi/
Meet the speaker:
Dr Anups De Silva - Consultant Gastroenterologist
Dr de Silva has been a Consultant Gastroenterologist for over 18 years and is the Clinical Lead for Inflammatory Bowel Diseases at NNUH. He is Honorary Senior Lecturer at the University of East Anglia, Norwich Medical School. He carried out his speciality training in London before taking up Consultant posts in the East of England. He is responsible for formulating regional high-cost drugs pathways in conjunction with his local Clinical Commissioning Group. He is an accredited bowel cancer screening colonoscopist and therapeutic endoscopist.
Meet the sponsor:
Tillotts are specialists in gastrointestinal health (GI) with over 30 years’ experience developing and manufacturing treatments for inflammatory bowel disease. Tillotts now have over 2 million patient years’ experience in the treatment of ulcerative colitis. With a development pipeline of new and innovative medicines for patients with diseases of the digestive system Tillotts are passionate about GI.
Tillotts are proud to support and sponsor the IBD Registry and Crohn’s & Colitis UK.
Tillotts are part of the Zeria Group. Visit www.tillotts.co.uk.